bioAffinity Technologies
BIAF | NASDAQ
$2.00
-$0.20 (-9.09%)
At close: Nov 16, 2026, 4:00 PM ET
$2.10
+$0.10 (+5.00%)
After-hours:
Nov 16, 2026, 7:34 PM ET
-9.09%
(1D)No price chart data available for 1D timeframe.
Rating
39.2
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #548/1021 (Top 54%)
Key Statistics
Market Data
Market Cap $12.57M
1D Range
1.96 2.13
52W Range
1.96 71.10
Valuation (TTM)
PE -0.04
PB 3.21
EV/EBITDA -0.87
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $0.00
Cash Flow
FCF Yield -103.2%
SBC Adj. FCF Yield -105.9%
SBC Impact -2.6%
Margins
Gross Margin -50.1%
Operating Margin -246.1%
FCF Margin -234.8%
Growth (CAGR)
Revenue 3Y | 5Y 158.1% |
39.8%
Dil EPS 3Y | 5Y 63.7% |
59.9%
FCF 3Y | 5Y -29.8% |
-28.4%
Returns
ROA -204.0%
ROE -331.0%
ROIC -251.3%
Financial Health
Net Cash
$1.05M
Current Ratio 1.51
Interest Coverage -270.95
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lun...
Sector Healthcare
Industry Medical - Diagnostics & Research
Employees 57
IPO Date Sep 1, 2022
Website www.bioaffinitytech.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 6, 2026
EPS
-$5.89
Beat +81.30%
YoY:
-24.26% REV
$1.07M
Miss -43.82%
YoY:
-25.99%Next Earnings
Apr 5, 2027
EPS Est
Pro
Rev Est
Pro
Add to Watchlist
Select watchlists to add or remove BIAF